Generic simvastatin cost effective in wider population than current guidelines indicate

Generic simvastatin is cost effective in a much wider population than indicated in current guidelines, according to a new cost-effectiveness study published online in Circulation: Cardiovascular Quality and Outcomes. The Heart Protection Study Collaborative Group combined data from the 20,000 patient HPS study with cost data from the US to estimate the effectiveness of simvastatin for people at different levels of risk. They concluded that generic simvastatin “appears to be very cost-effective for individuals (independent of their age) with annual risks of major coronary and other vascular events well below the levels currently required by national guidelines. As a consequence, existing guidelines should be modified to extend statin treatment to a much wider population.”

Speak Your Mind